Streetbeat News

Products Services

NVS

Novartis reported significant Phase III data for Fabhalta (iptacopan) in treating C3 glomerulopathy (C3G), showing a 35.1% reduction in proteinuria compared to placebo. The drug also showed numerical improvement in eGFR over 6 months and a favorable safety profile. C3G is a rare kidney disease with no current treatments, and Fabhalta targets its underlying cause.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:51 am

NVS

Novartis' Phase III data for atrasentan shows a significant reduction in proteinuria, enhancing its IgA Nephropathy (IgAN) portfolio. The ALIGN study demonstrated a 36.1% reduction in proteinuria with atrasentan plus supportive care compared to placebo. This positions Novartis to address the needs of patients with this rare kidney disease.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:49 am

VERA

Vera Therapeutics presented positive 72-week data from its Phase 2b ORIGIN study of Atacicept in IgAN at the 61st European Renal Association Congress, showing eGFR stabilization and rapid hematuria improvement.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:38 am

BNTX

MediLink Therapeutics and BioNTech have enhanced their strategic partnership with a new collaboration involving TMALIN ADC technology. MediLink will receive an upfront payment of $25 million and could earn up to $1.8 billion in milestone payments, along with tiered royalties on future sales. MediLink also holds the right of first negotiation for future collaborations in specific markets.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:35 am

HTHIY

RHHBY

Roche and Hitachi High-Tech have extended their 46-year partnership to advance diagnostic testing. The renewed 10-year contract aims to accelerate the availability of new solutions, including the upcoming launches of cobas® c703 & ISE neo units and cobas® Mass Spec solution.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:27 am

INSM

Insmed is set to discuss the topline results from its Phase 3 ASPEN study of Brensocatib in patients with bronchiectasis. A conference call will take place on Tuesday, May 28, 2024, at 8:00 am ET.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:17 am

SNY

Sanofi's Sarclisa has been accepted for FDA priority review for treating transplant-ineligible newly diagnosed multiple myeloma, based on positive results from the IMROZ phase 3 study. If approved, it would be the first anti-CD38 therapy in combination with standard-of-care treatment for this patient group.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:13 am

SATS

Hughes Network Systems, a subsidiary of EchoStar (NASDAQ:SATS), introduced its Low Earth Orbit (LEO) Electronically Steerable Antenna (ESA) for In-Flight Entertainment & Connectivity (IFEC) at the Aircraft Interiors Expo (AIX). This new technology aims to revolutionize aviation connectivity with high-speed, low-latency internet.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:12 am

RTX

RTX's Collins Aerospace and Panasonic Avionics have launched MAYA, a next-generation business class suite, at the 2024 Aircraft Interiors Expo in Hamburg, Germany. This new product aims to redefine comfort, passenger immersion, accessibility, and sustainability in air travel.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:11 am

NDAQ

Nasdaq (NASDAQ:NDAQ) and FIA Tech have announced a partnership to enhance post-trade data processing in the exchange-traded derivative market. Nasdaq will integrate its Real-Time Clearing platform into FIA Tech's Trade Data Network.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 7:08 am